The Los
Angeles-based AIDS Healthcare Foundation is blasting
drugmaker Tibotec, a subsidiary of Johnson &
Johnson, for what it says is an expected high price
tag for the newly approved protease inhibitor
Prezista, which is designed to treat drug-resistant HIV
infections. The Food and Drug Administration approved
Prezista on Friday. AHF says it expects Tibotec to
price Prezista well above the cost of other protease
inhibitors--as much as $26 per day or nearly $9,500
annually. And given that Prezista requires a small
booster dose of Norvir, a protease drug whose price
was quadrupled by drugmaker Abbott Laboratories in 2004, the
cost of Prezista treatment could be alarmingly high, AHF
says.
"We salute
Tibotec for the development of this promising new HIV/AIDS
drug and urge them to price this lifesaving medicine
fairly," says Michael Weinstein, AHF president, in a
press statement. "As with many AIDS drugs before it,
we anticipate that the cost of Prezista will simply be
out of the price range for most AIDS patients and threatens
to further stress Medicaid and AIDS Drug Assistance
Programs nationwide, many of which already have
waiting lists." (The Advocate)